
|Articles|July 1, 2006
Oncology NEWS International
- Oncology NEWS International Vol 15 No 7
- Volume 15
- Issue 7
Phase III Trial of Enzastaurin for NHL Patients Initiated
Phase III Trial of Enzastaurin for NHL Patients Initiated
Advertisement
INDIANAPOLISEli Lilly has initiated a randomized, placebo- controlled phase III trial of its experimental agent enzastaurin as maintenance therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma (NHL) who have achieved remission after first-line therapy. In early clinical studies, enzastaurin, an oral serinethreonine kinase inhibitor, showed promising activity in NHL.
Articles in this issue
almost 20 years ago
High-Quality Screening Colonoscopy Priority for GI Docsalmost 20 years ago
Genentech Seeks Expanded Use of Avastin in Breast Canceralmost 20 years ago
Denosumab Suppresses Bone Resorption in Breast Ca Metsalmost 20 years ago
FDA Approves Priority Review of Merck's Zolinza (Vorinostat)almost 20 years ago
FDA Approves Revlimid for Myeloma Rxalmost 20 years ago
Real-Time RT Planning, Delivery in the Bronxalmost 20 years ago
Racial Disparities in Prostate Ca Recurrencealmost 20 years ago
HNPCC Pts May Reject Prophylactic Subtotal ColectomyNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Advertisement
Related Content
Advertisement





Latest CME
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Zenocutuzumab in NRG1+ Cholangiocarcinoma Post Systemic Therapy
2
Daraxonrasib Shows Anti-Tumor Activity in Pretreated RAS+ Pancreatic Cancer
3
FDA Clears AI Stratification Tool in HR+/HER2– Invasive Breast Cancer
4
FDA Accepts sNDA for Taletrectinib in ROS1-Positive NSCLC
5














































